Canada Life’s Haemonetics HAE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.52M Hold
27,018
﹤0.01% 1238
2025
Q4
$2.17M Sell
27,018
-8,420
-24% -$566K ﹤0.01% 1130
2025
Q3
$1.71M Buy
35,438
+1,266
+4% +$78.4K ﹤0.01% 1287
2025
Q2
$2.55M Buy
34,172
+2,987
+10% +$198K ﹤0.01% 1096
2025
Q1
$1.98M Sell
31,185
-14,577
-32% -$991K ﹤0.01% 1192
2024
Q4
$3.57M Hold
45,762
0.01% 1002
2024
Q3
$3.68M Sell
45,762
-712
-2% -$57.5K 0.01% 1026
2024
Q2
$3.85M Sell
46,474
-4,254
-8% -$374K 0.01% 964
2024
Q1
$4.33M Buy
50,728
+5,933
+13% +$466K 0.01% 874
2023
Q4
$3.82M Buy
44,795
+4,795
+12% +$415K 0.01% 907
2023
Q3
$3.58M Buy
40,000
+3,117
+8% +$278K 0.01% 894
2023
Q2
$3.14M Sell
36,883
-3,607
-9% -$305K 0.01% 954
2023
Q1
$3.35M Sell
40,490
-1,144
-3% -$92.6K 0.01% 963
2022
Q4
$3.28M Buy
41,634
+6,432
+18% +$517K 0.01% 973
2022
Q3
$2.61M Buy
35,202
+3,979
+13% +$286K 0.01% 1024
2022
Q2
$2.03M Buy
31,223
+3,337
+12% +$197K 0.01% 1149
2022
Q1
$1.81M Buy
27,886
+2,018
+8% +$110K ﹤0.01% 1253
2021
Q4
$1.37M Buy
25,868
+1,946
+8% +$119K ﹤0.01% 1391
2021
Q3
$1.7M Buy
23,922
+4,619
+24% +$291K ﹤0.01% 1273
2021
Q2
$1.29M Sell
19,303
-404
-2% -$28.6K ﹤0.01% 1395
2021
Q1
$2.19M Sell
19,707
-1,535
-7% -$190K 0.01% 1087
2020
Q4
$2.52M Sell
21,242
-2,605
-11% -$280K ﹤0.01% 1023
2020
Q3
$2.08M Sell
23,847
-1,461
-6% -$128K ﹤0.01% 1042
2020
Q2
$2.27M Sell
25,308
-1,118
-4% -$113K 0.01% 1008
2020
Q1
$2.63M Buy
26,426
+1,862
+8% +$202K 0.01% 838
2019
Q4
$2.8M Buy
+24,564
New +$2.97M 0.01% 944
2019
Q3
Sell
-29,453
Closed -$3.54M 1612
2019
Q2
$3.54M Sell
29,453
-2,259
-7% -$222K 0.01% 878
2019
Q1
$2.77M Sell
31,712
-188
-0.6% -$17.1K 0.01% 864
2018
Q4
$2.96M Buy
31,900
+1,812
+6% +$190K 0.01% 828
2018
Q3
$3.45M Sell
30,088
-732
-2% -$75.8K 0.01% 850
2018
Q2
$2.76M Sell
30,820
-39,471
-56% -$3.33M 0.01% 960
2018
Q1
$5.14M Buy
70,291
+1,610
+2% +$110K 0.01% 700
2017
Q4
$3.99M Sell
68,681
-3,508
-5% -$185K 0.01% 789
2017
Q3
$3.12M Sell
72,189
-4,650
-6% -$193K 0.01% 886
2017
Q2
$3.03M Buy
76,839
+3,050
+4% +$125K 0.01% 889
2017
Q1
$2.99M Buy
73,789
+4,986
+7% +$195K 0.01% 896
2016
Q4
$2.77M Sell
68,803
-995
-1% -$37.5K 0.01% 905
2016
Q3
$2.53M Buy
69,798
+3,011
+5% +$103K 0.01% 924
2016
Q2
$1.94M Buy
66,787
+60,425
+950% +$1.83M 0.01% 1041
2016
Q1
$222K Hold
6,362
﹤0.01% 1254
2015
Q4
$205K Hold
6,362
﹤0.01% 1266
2015
Q3
$206K Buy
6,362
+2,600
+69% +$97.8K ﹤0.01% 1239
2015
Q2
$155K Hold
3,762
﹤0.01% 1530
2015
Q1
$168K Hold
3,762
﹤0.01% 1445
2014
Q4
$140K Hold
3,762
﹤0.01% 1515
2014
Q3
$132K Hold
3,762
﹤0.01% 1465
2014
Q2
$132K Hold
3,762
﹤0.01% 1383
2014
Q1
$122K Hold
3,762
﹤0.01% 1332
2013
Q4
$160K Buy
+3,762
New +$155K ﹤0.01% 1195

Other funds holding HAE

Canada Life's HAE Position: Q1 2026 in Review

Canada Life held its Haemonetics (HAE) position steady in Q1 2026 at 27,018 shares worth $1.52M. The position accounts for ﹤0.01% of the portfolio, ranked #1238.

Canada Life first reported a position in HAE in Q4 2013 and has held it in 49 quarters since. The position peaked at $5.14M in Q1 2018. 324 funds tracked by Wall St. Rank hold HAE as of Q1 2026.

  • Canada Life held 27,018 shares of Haemonetics worth $1.52M as of Q1 2026.
  • Canada Life left its Haemonetics share count unchanged in Q1 2026.
  • Haemonetics made up ﹤0.01% of Canada Life's portfolio in Q1 2026, its #1238 holding.
  • Canada Life first reported a position in Haemonetics in Q4 2013 and has held it in 49 quarters since.
  • Canada Life's Haemonetics position peaked at $5.14M in Q1 2018.
  • 324 funds tracked by Wall St. Rank held Haemonetics as of Q1 2026.

Based on Canada Life's 13F filing for Q1 2026, filed 14 May 2026.